Your browser doesn't support javascript.
Can sodium-glucose co-transporter-2 (SGLT-2) inhibitor reduce the risk of adverse complications due to COVID-19? - Targeting hyperinflammation.
Alshnbari, Afnan; Idris, Iskandar.
  • Alshnbari A; Royal Derby Hospital Centre, University of Nottingham, Derby, UK.
  • Idris I; Royal Derby Hospital Centre, University of Nottingham, Derby, UK.
Curr Med Res Opin ; 38(3): 357-364, 2022 03.
Article in English | MEDLINE | ID: covidwho-1612282
ABSTRACT
Sodium-glucose co-transporter-2 (SGLT-2) inhibitors are antidiabetic drugs with numerous pleiotropic and positive clinical effects, particularly regarding a reno-cardiovascular protective effect. More recent studies, including from our laboratory, have highlighted some novel anti-inflammatory activity of SGLT-2 inhibitors. This may confer a theoretical advantage in mitigating excessive cytokine production and inflammatory response associated with serious COVID-19 infection. Specifically, earlier research has demonstrated that SGLT-2 inhibitors are associated with a notable decrease in inflammatory indicators, for example, C-reactive protein, ferritin, and interleukin-6. Furthermore, SGLT-2 inhibitors exhibit a favourable impact on the vascular endothelium function; this could pertinence the prophylaxis of the thrombotic issues that arise in SARS-CoV-2. This review provides an overview of the COVID-19 indirect immune response mechanisms impacting the cardiovascular system and the possible effect of SGLT-2 inhibitors on the management of COVID-19.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Sodium-Glucose Transporter 2 Inhibitors / COVID-19 Drug Treatment / Inflammation Type of study: Prognostic study Limits: Humans Language: English Journal: Curr Med Res Opin Year: 2022 Document Type: Article Affiliation country: 03007995.2022.2027141

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Sodium-Glucose Transporter 2 Inhibitors / COVID-19 Drug Treatment / Inflammation Type of study: Prognostic study Limits: Humans Language: English Journal: Curr Med Res Opin Year: 2022 Document Type: Article Affiliation country: 03007995.2022.2027141